Telomir Pharmaceuticals
TELO
34 hedge funds and large institutions have $13.1M invested in Telomir Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 15 increasing their positions, 5 reducing their positions, and 0 closing their positions.
655% more capital invested
Capital invested by funds: $1.74M → $13.1M (+$11.4M)
200% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 5
36% more funds holding
Funds holding: 25 → 34 (+9)
5.69% more ownership
Funds ownership: 1.22% → 6.91% (+5.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.47M |
| 2 |
BlackRock
New York
|
+$1.36M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$840K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$237K |
| 5 |
SEM
Suncoast Equity Management
Tampa,
Florida
|
+$131K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
New York State Common Retirement Fund
Albany,
New York
|
-$56.6K |
| 2 |
Citigroup
New York
|
-$15K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$10.4K |
| 4 |
RhumbLine Advisers
Boston,
Massachusetts
|
-$4.32K |
| 5 |
CF
Corebridge Financial
Houston,
Texas
|
-$78 |
TELO Hedge Fund Activity: Q3 2024 in Review
34 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Telomir Pharmaceuticals (TELO) for Q3 2024, worth a combined $13.1M — up 655% from $1.74M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new TELO positions and 0 closed out — a net gain of 9 holders — while 15 added to existing stakes and 5 trimmed.
The largest buyer was Vanguard Group, adding an estimated $5.47M. The largest seller was New York State Common Retirement Fund, cutting an estimated $56.6K.
- 34 institutional investors held Telomir Pharmaceuticals (TELO) as of Q3 2024, up from 25 in Q2 2024.
- Funds reported $13.1M of Telomir Pharmaceuticals stock for Q3 2024, up 655% quarter-over-quarter.
- 9 funds opened new Telomir Pharmaceuticals positions in Q3 2024 and 0 closed out, a net change of +9 holders.
- The largest Telomir Pharmaceuticals buyer in Q3 2024 was Vanguard Group, an estimated $5.47M added.
- The largest Telomir Pharmaceuticals seller in Q3 2024 was New York State Common Retirement Fund, an estimated $56.6K sold.
Based on aggregated 13F filings for Q3 2024.